In developing our stem cell processing method, we looked at four things: quality, safety, flexibility, and cost – the same things every parent should consider when choosing a cord blood bank.
The result is PREMIERMAX® – the PREMIER process that results in MAXIMUM stem cell recovery and transplant safety.
Every cord blood collection is different, so we developed a process that would yield the highest number of stem cells under all circumstances.
Many factors contribute to the number of stem cells in a cord blood collection. Variables like the number of previous pregnancies, the mother’s age, the volume of cord blood collected, and the processing method all come into play.
Since the maternal factors and delivery room collection are a given, the processing method is the key to getting the most stem cells possible from newborn cord blood.
Having been in the industry since 1995, we have seen cord blood banking come a long way since the days of hetastarch, a first generation method. Over years of processing both public and private cord blood collections, we have developed a method the delivers the best results for patients.
Clinical research by the US National Library of Medicine of the National Institute for Health has validated our process. A team of scientists from the Cell Therapy Research Institute and the Newcastle Centre for Cord Blood published two separate studies that reached the same conclusion – our process is superior to hetastarch.
The unbiased research team concluded that our process “is consistently the best performer over the whole range of analysis.” It provides the most efficient recovery, the highest red cell depletion, and reduces the risk for contamination.
Our process recovers almost 75% of your newborn’s stem cells, while hetastarch recovers a little more than half (56.48%). This means that many more precious stem cells are being recovered for future use with PREMIERMAX®.
In any laboratory that processes blood, preventing contamination is a priority. Again, the researchers found that our chosen method is superior. We use a closed system, meaning that the risk is much lower for transfer of contaminates from other surfaces to your child’s cord blood.
However, safety goes beyond preventing contamination. It also means ensuring that the transplant unit offers the lowest risk of adverse reaction in the patient. Two things come into play here: red cell depletion and the cryo-preservative.
Why is it important to separate the stem cells from the whole blood? For a few reasons. First, there’s no need to store plasma or red blood cells as they don’t contain any stem cells and aren’t needed for transplant.
More importantly, red blood cells tend not to survive the freezing and thawing process. Their cell membranes rupture, spilling the contents, which include the hemoglobin and empty membrane sacks called red cell “ghosts”. This can make patients sick following transplant.
The fewer the red blood cells, the safer the transplant. Our process removes 98.5% of the red blood cells, compared to 33.45% for hetastarch – a clear difference.
When it comes to transplant safety, the cryo-preservative also matters. It needs to protect the stem cells from damage during storage and the patient from toxic chemicals during transplant. Our preservative keeps cells from being damaged and is less toxic than other products currently being used by other cord blood banks.
The amount of cord blood varies widely and you never know how much you will get until you are in the delivery room. Here’s why that matters:
Research shows something really surprising when it comes to the amount of Total Nucleated Cells (TNCs) extracted from different volumes of cord blood. When using hetastarch, the higher the volume of cord blood the LOWER the yield of CD34+! This means that even though your physician collects a high volume of cord blood, the hetastarch becomes diluted and doesn’t work as effectively, leaving a higher percentage of stem cells behind to be discarded. Since hetastarch already yields only about 56% of the stem cells, higher cord blood volumes could mean over half of your child’s stem cells are discarded.
With our PREMIERMAX®, you get the same yield, regardless of volume. That means that whether you collect a lot of cord blood or a little, you can be confident that you will always get the most out of your collection – on average almost 75 percent of the stem cells.
Why take chances, when you won’t know how much cord blood is in your collection until your baby is born? At that point, it’s too late to change banks.
Mr. Kondorosi has been involved with the hospitality and hotel industry for most of his life. From 1969 through 1985, he held various positions at the international InterContinental Hotels chain, including various senior management roles. After his transitioning to the USA, he moved into the real estate business and held a variety of positions. Recently he has held te position of Director of Sales for Prestige Homes, Inc. part of Goldrich and Kest Industries headquartered in California since 1957. Mr. Kondorosi represented the successful sale of 386 homes in the Bel Air Crest Development, including re-sales over the past several years, various high end listings and sales in prominent locations such as Malibu, Pacific Palisades, Bel Air, Beverly Hills and other parts of the west-side Los Angeles area.
Mr. Kondorosi is also the founder and President of EDKO Trade, Inc., and international real estate and trading company involved in promoting and closing transactions between various companies and individuals located around the world. Since 2000, he has also been involved in various international and foreign innovative startup companies in various capacities including CEO, board member or in a consulting role. Mr. Kondorosi received a Juri Doctor degree from Janus Pannonius University in Hungary in international law. He also was a professor at the Budapest Business School / Faculty of Commerce, Catering and Tourism in Hungary.
In addition, Mr Kondorosi has served on the Board for the Regency Club from 2008 through 2011, a private business organization started by David Murdock 30 years ago in Los Angeles.
Ms. Sardone has over 30 years of clinical laboratory experience as a Clinical Laboratory Technologist, including over 25 years with Central Florida Regional Hospital (CFRH). She was Supervisor of Quality Assurance, Safety and Education at CFRH for 11 years, held the positions of Blood Bank Supervisor for 11 years, and Hematology Supervisor for 1 year. She has participated in both sides of the inspection process, serving on the College of American Pathologists Inspection team for CAP Hospital Accreditation in Florida, and assisting in receiving accreditation by The Joint Commission (TJC), American Association of Blood Banks (AABB), and Food and Drug Administration (FDA) through the inspections of the clinical laboratory.
Ms. Sardone is licensed by the State of Florida as a Clinical Laboratory Technologist in Immunohematology, Hematology, Serology and Clinical Chemistry. She is a certified Clinical Laboratory Technologist with the American Society of Clinical Pathologists (ASCP).
Ms. Sardone serves as Manager of Quality Assurance and Regulatory Affairs at Cord For Life®, Inc. overseeing all licensing and regulatory agencies to ensure that the highest quality in all aspects of cord blood collection, processing, and storage is maintained.
Ms. Sardone’s skills and knowledge in blood banking and quality assurance have enabled her to establish, implement and maintain a superior quality system that meets and exceeds all standards and regulatory requirements for Cord For Life®, Inc.
Mr. Hudspeth has over 17 years of clinical laboratory experience as a certified Medical Technologist (ASCP), including ten years with the University of North Carolina Hospitals. Mr. Hudspeth is licensed by the State of Florida as a Clinical Laboratory Supervisor in Immunohematology, Hematology, Serology, Clinical Chemistry, Molecular Pathology and Microbiology as well as a Clinical Laboratory Scientist, is a registered Technologist with the American Society of Clinical Pathologists and a member of the American Society of Blood and Marrow Transplantation (ASBMT).
He has also enjoyed teaching Immunology to Clinical Laboratory Science and medical school students at UNC while working in the UNCH clinical labs. At Cord For Life®, Mr. Hudspeth serves as Chief Operating Officer, overseeing all operations and the daily laboratory operations to ensure that the highest quality in all aspects of donor selection and cord blood collection, processing, and storage is maintained. He also works with Quality Assurance to ensure full compliance by Cord For Life® to all applicable regulations. Mr. Hudspeth has sat on numerous cord blood focused committees and advisory groups.
Additionally, Mr. Hudspeth served as the Clinical Investigator for Cord For Life® as they evaluated and approved a new processing methodology to isolate stem cells from cord blood while depleting the unwanted red cells. Mr. Hudspeth works with groups, individuals, or government agencies to bring cord blood banking to countries around the world. He is responsible for training medical professionals worldwide in cord blood processing at our Florida location. In addition, he travels overseas to assist in the initial setup and implementation of the new facilities to ensure their compliance and quality. Mr. Hudspeth has assisted in opening new cord blood facilities in Europe and in SE Asia.
Don joined Sanofi Pasteur VaxDesign in 2005 and has served as Director of Immunological Research since 2009. He has had a long-standing interest in the immune system, particularly the interaction between viruses and elements of the adaptive immune system, since initiating his graduate studies at Emory University in Atlanta, GA.
As a post-doctoral fellow at the University of Virginia, he was awarded funding from the Cancer Research Institute and received an Interdisciplinary Training Grant in Immunology from the National Institutes of Health to study CD8+ T cell immunity against influenza virus.
At VaxDesign, Don leads a team developing and optimizing the MIMIC® System to permit the evaluation of human adaptive immunity (cellular and humoral responses) against vaccine candidates, biologics, and other immunomodulators in a pre-clinical setting. He is an author on a variety of patents and peer-reviewed journal publications.
Mrs. Cable brings over 20 years of experience to Cord For Life® directing the Client Services, Account Management and Personnel departments. She began working in the cord blood industry in December of 2006. In addition, Ms. Cable is actively involved in marketing for the company.
Dr. Richard R. Gammon joined Florida’s Blood Centers (FBC) in 2005 and is responsible for ensuring that the organization’s medical practices, policies and testing remain at the forefront of the blood-banking industry. He received his undergraduate degree from Gannon University in Erie, Pennsylvania and medical degree from Hahnemann University in Philadelphia.
He completed his residency at The Ohio State University and his fellowship at the University of Virginia. He also serves as an assistant professor of pathology at the University of Central Florida College of Medicine. He has served as President and Technical Committee Chair of the Florida Association of Blood Banks. He currently serves as the Chair of the Scientific Medical and Technical Committee and Chair of the Journal Club for America’s Blood Centers.
He is an assessor and abstract reviewer for AABB and is a manuscript reviewer for the journal Transfusion. He is the co-recipient of a 2011 ABC Foundation Grant for the Get Healthy Wellness Program. Dr. Gammon’s research has been published in various peer-reviewed journals and he has been a featured speaker at numerous national and international conferences on blood banking and transfusion medicine.
Dr. Pollock was originally from Ohio where he majored in pharmacy at Ohio Northern University. After graduation he worked as a pharmacist and attended The Ohio State University where he majored in chemistry and graduated in biochemistry.
In 1992 he attended Wright State University School of Medicine in Dayton Ohio, after graduating from medical school he completed his residency at Orlando Regional Medical Center in anatomic and clinical pathology, then a two year fellowship in clinical molecular genetics at All Children’s Hospital in St Petersburg Florida. After completing his fellowship in genetics, he became Medical Director for Central Florida Blood Bank for 3 years where he took great interest in the stem cell donation program.
After leaving the blood bank, Dr Pollock became Assistant Director in Molecular Genetics for the Centers of Advanced Diagnostics which at the time was a division of Ameripath. After the restructuring of the Orlando operation, Dr Pollock found himself back in blood banking. He was medical director for BloodNetUSA in Lakeland, Florida prior to its merger with Florida Blood Services.
During the last two years of Medical School, Dr. Irrgang was in the United States Navy 1915 Ensign Program and completed a clerkship at the Naval Hospital at Charleston, South Carolina as well as a research clerkship at the Naval Aerospace Institute at Pensacola, Florida.
Dr. Irrgang completed her four year Pathology residency at Baylor University Medical Center, and her internship at the University District Hospital, Rio Piedras in San Juan, Puerto Rico. Currently, Dr. Irrgang is Board Certified in Anatomic and Clinical Pathology and licensed in the states of South Carolina, Texas, New Jersey and Florida and she is an Associate Medical Examiner at the District Nine Medical Examiners Office.
Dr. Irrgang is a fellow at numerous organizations including; The College of American Pathologists, National Association of Medical Examiners, Florida Association of Medical Examiners, Seminole County Medical Society, and the Florida Medical Society.